Sponsor Deadline
Posted: 3/25/2022

Acromegaly Research- United States

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP. 

Research areas to be considered for funding include:

• Acromegaly:

o Morbidity and mortality in Growth Hormone Excess

o Impact and/or needs of patients with Growth Hormone Excess during the pediatric, transitional years and young adult life

o Novel strategies including Quality of Life and Patient Reported Outcomes to evaluate and treat Growth Hormone Excess

o Early diagnosis and treatment of Growth Hormone Excess

o Pathophysiology of Growth Hormone Excess and/or deficiency and/or action 

Grant Application due date: June 30, 2022 

Eligibility Requirements

Geographic Scope • United States

• The institution and principal investigator (PI) must be based in one of the eligible countries noted above. • Only organizations are eligible to receive grants, not individuals or medical practice groups. • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. • Applicant must be affiliated with a host institution 

Amount Description

Individual projects requesting up to $100,000 will be considered. Pfizer anticipates awarding 1 grant.  

Funding Type